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ABSTRACT 
 
Towards the Synthesis of Possible Dual Inhibitors of Fatty Acid Synthase and the Human 20S  
Proteasome as Anticancer Agents. (May 2013) 
 
 
James Thomas Moore 
Department of  
Chemistry 
Texas A&M University 
 
 
Research Advisor: Dr. Daniel Romo 
Department of  
Chemistry 
 
  
Human fatty acid synthase (FAS) and the human 20S proteasome are useful targets for 
anticancer chemotherapy, and the latter target has been validated as a target for treatment of 
various forms of cancer. Belactosin C, cinnabaramide A, and orlistat are three β-lactone 
containing compounds that have been shown to inhibit either FAS or the human 20S proteasome, 
leading to tumor cell death via apoptosis. This project describes the design and synthesis of novel 
dual inhibitors of these two enzyme targets premised on these three β-lactone containing 
compounds with the goal of finding a more potent and “druggable” inhibitor. The key step in this 
synthesis of the described synthetic strategy toward these dual inhibitors is a nucleophile 
catalyzed aldol lactonization (NCAL) process to form the γ-lactam fused β-lactone core. 
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NOMENCLATURE 
 
 
NCAL   Nucleophile-Catalyzed Aldol Lactonization 
 
R   alkyl group 
 
Bn   benzyl   
 
i-Pr   iso-propyl 
 
Me   methyl 
 
Et   ethyl 
 
Ph   phenyl 
 
TFA   triflouroacetic acid 
 
PPY   4-pyrrolidinopyridine 
 
THF   tetrahydrofuran 
 
DEAD   diethyl azodicarboxylate 
 
PPh3   triphenyl phosphine 
 
DMF   dimethyl formamide 
 
PCC   pyridinium chlorochromate 
 
pTSA   p-toluenesulfonic acid 
 
Tos   p-toluenesulfonate 
 
FAS   fatty acid synthase 
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CHAPTER I 
 
INTRODUCTION 
 
 
In many types of cancers, fatty acid synthase (FAS) is an overexpressed protein that regulates the 
synthesis of the fatty acids necessary for the growth of the tumor cell.
1
 Another protein, the 
human 26S proteasome, is responsible for the timely degradation of numerous regulatory 
proteins in the eukaryotic cell.
2
 Incidentally, studies have shown that the inhibition of either FAS 
or the 20S proteolytic core of the human 26S proteasome lead to tumor cell death via apoptosis 
for various forms of cancer, including multiple myeloma and mantle cell lymphoma. Generally, 
normal cells can survive therapeutic doses of proteasome and FAS inhibitors, making these drugs 
even more attractive candidates for the treatment of various forms of cancer.
1,2
  
 
One common characteristic of a group of inhibitors is the presence of a β-lactone, as seen in 
Figure 1. Proteasome inhibitors have been used in the treatment of advanced multiple myeloma 
since 2003, with approximately one third of patients with relapsed and refractory multiple 
myeloma showing significant clinical benefit.
 3
 One compound shown in Figure 1, 
salinosporamide A, has already entered phase I human clinical trials for the treatment of multiple 
myeloma.
4
  
 
Remarkably, the mechanism of proteasome and FAS inhibition with β-lactone inhibitors occur 
through very similar mechanisms that involve the acylation of hydroxyl moieties in the active 
site of both proteins with the β-lactone, as seen in Figure 2.5 The result is a trans-esterification 
within the active sites, yielding a non-functioning protein.  
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structures of various inhibitors containing the β-lactone moiety. 
 
 
 
 
 
 
 
 
Figure 2. Reaction mechanism that depicts the inhibition of either FAS or the 20S 
proteasome.
1,2,9 
β-Lactone Moiety 
Orlistat: FAS Thioesterase  
Domain Inhibitor
1 
Cinnabaramide A:  
Proteasome Inhibitor
7 
N-Cbz, O-Bn-(-)-Homobelactosin C: 
Proteasome Inhibitor
6 
Salinosporamide A: 
Proteasome Inhibitor
6 
Belactosin C: 
Proteasome Inhibitor
8 
Omuralide: Proteasome 
Inhibitor
6 
8 
 
In 2007, a derivative of orlistat and N-Cbz, O-Bn-(-)-homobelactosin C (shown in Figure 1) was 
synthesized and was shown to inhibit both FAS and the proteasome. As can be seen in Figure 3, 
YE-X02 is composed of a dipeptide chain consisting of L-alanine and L-ornithine coupled to a β-
lactone.
10
 This compound affects malignant cells thorough the targeting and inhibition of two 
different protein complexes, each of which induces preferential tumor cell apoptosis. Because of 
YE-X02’s ability to inhibit both FAS and the human 20S proteasome, numerous analogs of YE-
X02 consisting of various dipeptides were synthesized, each with a varying percentage of 
inhibition of both FAS and the human 20S proteasome.
11
  
 
 
 
 
Figure 3. Structure of dual proteasome and FAS inhibitor, YE-X02. 
 
It was also in 2007 that Ma, G. et. al. succeeded in synthesizing salinosporamide A and 
cinnabaramide A.
6,7,8
 The key step in their synthesis is the use of a nucleophile catalyzed aldol 
lactonization (NCAL) process in which the γ-lactam fused β-lactone is created in a single 
reaction.  
 
A likely reaction mechanism for the NCAL process is shown in Scheme 1. First, the carboxylic 
acid moiety is activated, followed by transacylation with 4-pyrrolidino pyridine. Subsequent 
deprotonation leads to an ammonium enolate, which leads to an aldol lactonization that produces 
9 
 
a γ-lactam fused β-lactone.6 However, a [2 + 2] cycloaddition mechanism via an intermediate 
ketene has not been excluded.
7
 
Scheme 1. Likely reaction mechanism for the formation of the γ-lactam fused β-lactone.6 
 
With such a versatile reaction, numerous analogs of the γ-lactam fused β-lactone inhibitors can 
be synthesized. It is through this NCAL process that an inhibitor that builds on the structures of 
YE-X02 and the γ-lactam fused β-lactone, such as cinnabaramide A, can be synthesized. It 
should be noted that the proposed γ-lactam fused β-lactone core possesses the opposite 
stereochemistry as salinosporamide A and cinnabaramide A. (Figure 4) 
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Figure 4. Depiction of the various inhibitors used to devise a dual inhibitor such as the one 
shown above. 
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CHAPTER II 
METHODS 
 
The retrosynthesis of a possible inhibitor derived from both YE-X02 and cinnabaramide A, 1, is 
shown in Figure 5.   
Figure 5. Retrosynthetic strategy for derivatives of YE-X02 and cinnabaramide A. 
 
In order to couple a dipeptide to the cinnabaramide A derivative, it must possess a non-
nucleophilic nitrogen containing functional group such as the azide in 2. The bis-cyclization of 
the compound can be achieved via an NCAL process, in which various carbocycle-fused β-
lactones have been synthesized.
6
 The carboxylic acid-azide intermediate 3 can be created via an 
amide coupling between the β-keto-thioester, 4, and β-azidoalanine, 5. This synthetic pathway 
can lead to various derivatives of cinnabaramide A and YE-X02.  
 
12 
 
The synthesis of this possible dual-inhibitor begins with the synthesis of β-azidoalanine, 5 
(Scheme 2). This will begin with treatment of L-serine, 6, with boc-anhydride, 7. The product, 
Boc-serine, 8, is subjected to Mitsunobu Esterification to yield Vederas’s β-lactone, 9.12 The 
amine is deprotected, then treated with sodium azide to afford β-azidoalanine.13 
Scheme 2. Synthetic route to β-azidoalanine. 
 
The synthesis of the β-keto thioester, 4, will begin with the reaction between thiophenol, 11, and 
octanoyl chloride, 12, to form thioester 13. This is then subjected to aldol reaction with 
acetaldehyde, 14, to yield the β-hydroxy thioester, 15.14 The alcohol is then oxidized to form the 
β-keto thioester (Scheme 3).    
 
Scheme 3. Synthetic route to β-keto thioester. 
 
Next, 4 and 5 is coupled via amide linkage, followed by a NCAL of keto acid 16 using modified 
Mukaiyama’s reagent, 17, and 4-pyrrolidino-pyridine to form bi-cyclic β-lactone core, 18.  
13 
 
Scheme 4. Coupling of azido-alanine and keto-thioester, NCAL, then dipeptide coupling to form 
the proposed dual-inhibitors. 
 
Table 1.  A list of proposed dual inhibitors. 
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The azide is then treated with triphenylphosphine followed by treatment of the resulting 
intermediate with various protected dipeptides (Scheme 4) to yield the dual inhibitors shown in 
Table 1. 
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CHAPTER III 
 
RESULTS 
 
The first step in the synthesis of the β-azidoalanine, 5, was the protection of L-serine, as seen in 
Scheme 5. 
 
 
 
Scheme 5. Boc-protection of L-serine. 
 
Boc-serine, 8, was isolated in this reaction as a clear oil. However, pure Boc-serine is actually a 
white solid, which suggests that the oil that was isolated is impure. So purification via trituration 
was attempted to try to isolate the Boc-serine. However, Boc-serine could not be isolated as a 
solid, presumably because of trace amounts of di-tert butyl carbonate that did not react in 
solution. However, the 
1
H NMR showed that there were only traces of this impurity. Therefore it 
was decided that the next reaction be attempted using this oil, which is shown in Scheme 6.  
 
 
 
Scheme 6. Synthesis of Vederas’s β-lactone.12 
 
Despite the fact that the Boc-serine was not pure, the reaction was able to form the β-lactone, 
however the yield was lower than that reported by Arnold, et. al. (44% compared to 72%). The 
following reaction is the deprotection of the amine in 9 (Scheme 7). 
16 
 
 
 
 
Scheme 7. Boc-deprotection followed by addition of azide functional group. 
 
In the publication by Arnold et. al.
12
, after 9 is treated with trifluoroacetic acid, the 
trifluoroacetate salt is then treated with p-toluenesulfonic acid and recrystallized to replace the 
trifluoroacetate anion with the tosylate anion. This is done to prevent the decomposition of the β-
lactone. However, the following reaction was attempted using the trifluoroacetate salt instead, in 
which we were pleased to find that it proceeded efficiently to provide β-azidoalanine, 5.  
 
The synthesis of the β-keto thioester, 16, begins with the reaction between thiophenol and 
octanoyl chloride, shown in Scheme 8. 
 
 
 
Scheme 8. Formation of thioester. 
 
In this reaction, thiophenol is a nucleophile and attacks the electrophilic carbonyl carbon. 
Hydrogen chloride is also formed in this reaction which makes the use of a base such as 
triethylamine necessary to neutralize this acid. After purification, the thioester was isolated with 
a 68% yield. 
 
17 
 
The next reaction is the aldol reaction between 13 and acetaldehyde, shown in Scheme 10. In this 
reaction, TiCl4 is used to make the α protons in 13 more acidic, making the formation of an 
enolate favorable. (Scheme 9)  
 
 
 
Scheme 9. Aldol reaction for the formation of the β-hydroxy-thioester.12 
 
Once acetaldehyde is added to the solution, the nucleophilic enolate attacks the electrophilic 
carbonyl in acetaldehyde. After aqueous work-up, the β-hydroxy thioester, 15, was isolated with 
a 68% yield.  
 
The final reaction for the synthesis of the β-keto thioester is the oxidation of the hydroxyl group 
of 15, shown in Scheme 10. 
 
 
 
Scheme 10. Oxidation of the β-hydroxyl group to form the β-keto thioester. 
 
Pyridinium chlorochromate (PCC), a mild oxidizing agent, is used in this reaction in order to 
ensure that the thioester is not cleaved. A brown oil is isolated from the column, however there 
were numerous compounds eluted from the column at the same time. Examination of the 
1
H 
NMR spectrum of this crude reaction mixture provided the identities of a few of the compounds 
found in the oil. A chemical shift found at 11.63 ppm possibly illustrates the characteristic enol 
18 
 
tautomer peak prevalent in β-dicarbonyl groups.   However, the large number of impurities in 
this 
1
H NMR spectrum makes it difficult to determine whether this reaction produced the desired 
product. Future studies will be conducted to determine whether this reaction really produced the 
β-keto thioester. 
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CHAPTER IV 
CONCLUSIONS AND FUTURE WORK 
 
As of this time, the synthesis route is proving to be promising in allowing for the production of 
these dual inhibitors. Once the proposed dual inhibitors are successfully synthesized, they will be 
assayed to determine strength of inhibition of both FAS and the human 20S proteasome. These 
results will then be evaluated to determine which dipeptide structure optimizes the inhibitory 
properties towards these two proteins. This process includes varying one structural moiety at a 
time followed by submitting these inhibitors to biological assays in order to determine if these 
new variables increase the compound’s inhibition properties. Molecular modeling will be used in 
order to determine what types of structural moiety variations will be considered. Experiments 
involving computer simulations are currently being carried out in order to approximate 
association and dissociation constants the inhibitors will have with the targeted protein active 
sites. This, in turn, aids in ruling out proposed inhibitors which will ultimately not be compatible 
and produce poor inhibition results before any time is spent synthesizing and assaying them.  
These results can potentially lead to a more effective treatment for various forms of cancer, 
which in turn can save millions of lives in the future. 
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APPENDIX 
EXPERIMENTAL PROCEDURES 
 
General Methods 
All chemicals were purchased from Aldrich and used without purification.  Reactions were 
monitored by thin layer chromatography (TLC) on silica Merck 60 F254.  TLCs were stained 
using potassium permanganate and annisaldehyde stain.  Purification of products was carried out 
via flash column chromatography using silica (60 Å, 230-400 mesh).  
1
H and 
13
C NMR 
characterization was performed on an Inova 300 MHz spectrometer.  Chemical shifts (δ) are 
expressed in ppm and are referenced to deuterated chloroform (δ 7.27 ppm) unless otherwise 
noted.  Multiplicities are represented as follows: s (singlet), d (doublet), t (triplet), q (quartet), dt 
(doublet of triplets), m (multiplet), bs (broad singlet). 
 
N-tert-butoxy-L-serine (8) 
 
 
 
To a solution of L-serine (6) (10.01 g, 95.15 mmol) in 1 N NaOH (200 mL, 8.02 g, 200.5 mmol) 
at 0°C, was added a solution of di-tert-butyl dicarbonate (20.97 g, 96.11 mmol) in 1,4-dioxane 
(100 mL). The resulting two phase solution was stirred at 0°C for 30 min, then at room 
temperature for an additional 4 h. The mixture was concentrated, then acidified to pH 2-3 by 
careful addition of 1 N HCl (~225 mL). The product was extracted with EtOAc (4 x 100 mL) 
and then the combined extracts were dried over anhydrous MgSO4, filtered, and then evaporated 
22 
 
in vacuo to afford boc-serine (8) (15.23 g, 78% yield) as a colorless oil and data matched that 
reported previously.
15
 Boc-serine was used in the following reactions without further 
purification. 
1
H NMR (300 MHz, CD3OD): δ 6.37 (d, J = 9 Hz, 1H), 4.22 (t, J = 6.6 Hz, 1H), 
4.09 (q, J = 6 Hz, 1H), 3.90 (dd, J = 3.6 Hz, 1H), 3.81 (dd, J = 3.6 Hz, 1H), 1.44 (s, 9H). 
 
N-(tert-butoxycarbonyl)-L-serine-β-lactone (8). 
 
 
 
To a stirred solution of PPh3 (6.39 g, 24.4 mmol) in anhydrous THF (100 mL) at -78°C was 
added 40% diethyl azodicarboxylate in toluene (11.10 mL, 24.4 mmol) dropwise over 20 min. 
After 10 min of additional stirring, a solution of Boc-L-serine (5.00 g, 24.4 mmol) in anhydrous 
THF (100 mL) was added dropwise over 20 min to the stirred solution at -78°C, then 3 h at 
20°C. Solvent was removed in vacuo, and the residue was chromatographed on silica gel 
(EtOAc/hexane 4.5:5.5) to afford 8 (2.05 g, 45% yield) as a white crystalline solid and data 
matched that previously reported.
12
 IR (CHCl3 cast): 3354 (s), 1832 (s), 1674 (vs), 1528 (s), 1287 
(m), 1100 (s) cm
-1
.  
1
H NMR (500 MHz, CDCl3): δ 5.53 (d, J = 10 Hz, 1H), 5.05 (dd, J = 5 Hz, 
1H), 4.47 (d, J = 6 Hz, 2H), 1.47 (s, 9H); 
13
C NMR (300 MHz, CDCl3): δ 170.0, 155.1, 81.5, 
66.6, 59.9, 28.2.   
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L-serine-β-lactone trifluoroacetate (21)  
 
 
 
 
Boc-L-serine-β-lactone (305 mg, 1.61 mmol) is treated with CF3COOH (5 mL) at 0°C for 10 
min. The excess CF3COOH is then removed in vacuo. The resulting oil is immediately taken to 
the next reaction. 
 
β-azidoalanine (5) 
 
 
 
To a stirred solution of trifluoroacetate salt 21 (3.21 mmol) in DMF (3 mL) is added a solution of 
NaN3 (115 mg, 1.77 mmol) in DMF (6 mL) at room temperature. The solution is allowed to stir 
for 3.5 h. The solvent is then evaporated in vacuo to afford 5 as a brown oil. Data obtained 
matched that previously reported.
13
 
1
H NMR (300 MHz, DMSO-d6): δ 9.57 (d, J = 6 Hz, 1H), 
4.34 (dd, J = 3.6 Hz, 1H), 3.79 (dd, J = 3 Hz, 1H), 3.76 (dd, J = 6 Hz, 1H). 
13
C NMR (300 MHz, 
DMSO-d6): δ 162.4, 60.2, 55.8.   
 
S-Phenyl Octanethioate (13) 
 
 
24 
 
To a 100-mL round-bottomed flask was added CH2Cl2 (30 mL), triethylamine (5.06 mL, 36.3 
mmol) and thiophenol (3.73 mL, 36.3 mmol). A solution of octanoyl chloride (6.20 mL, 36.3 
mmol) in 35 mL dichloromethane was added over 30 min while stirring the solution with a 
magnetic stirrer. Precipitating triethylammonium chloride made the reaction mixture turn to a 
turbid suspension. After 45 min of additional stirring the reaction was completed as monitored 
by TLC (hexanes, Rf = 0.43). The organic mixture was washed twice with 50 mL saturated 
sodium hydrogen carbonate solution and once with 50 mL brine. The organic layer was dried 
over anhydrous MgSO4, filtered and the solvent evaporated in vacuo to yield 3.68 g of S-phenyl-
octanethioate, 6, as a clear oil (48%). Data obtained matched that reported previously.
16
  
1
H 
NMR (300 MHz, CDCl3): δ 7.29-7.25 (m, 5H), 2.51 (t, J = 7.5 Hz, 2H), 2.31 (t, J = 7.8 Hz, 2H), 
1.63-1.56 (m, 4H), 1.25-1.21 (m, 4H), 0.77 (t, J = 1.8 Hz, 3H). 
 
S-phenyl 2-(1-hydroxyethyl)octanethioate (15)  
 
 
 
1 M TiCl4 in CH2Cl2 (9.51 mL, 25.38 mmol) and Et3N (4.13 mL, 29.61 mmol) were successively 
added to a stirred solution of phenyl-thioester 13 (5.00 g, 21.15 mmol) in CH2Cl2 (50 mL) at -
78°C under an atmosphere of N2. After stirring for 30 min, acetaldehyde (3.5 mL, 25.38 mmol) 
was added to the mixture. After 2.5 h of additional stirring at the same temperature, the reaction 
was completed as monitored by TLC (EtOAc/hexanes 3:7, Rf = 0.42). The mixture was poured 
into ice water, which was extracted with Et2O (2 x 100 mL). The organic phase was then washed 
with water, brine, and then dried (MgSO4) and concentrated. The resulting oil was 
25 
 
chromatographed on silica using EtOAc/hexanes (3:7) as eluent to afford the β-hydroxy 
thioester, 15 as a clear oil (2.28 g, 64%). 
1
H NMR (300 MHz, CDCl3): δ 7.46-7.40 (m, 5H), 4.07 
(quint, J = 6 Hz, 1H), 4.00 (quart, J = 6 Hz, 1H), 2.71 (quint, J = 6 Hz, 1H), 1.89-1.60 (m, 2 H), 
1.54-1.28 (m, 8 H), 0.91 (t, J = 3 Hz, 3H). 
13
C NMR (300 MHz, CDCl3): δ 201.4, 134.5, 129.7, 
129.4, 127.7, 68.7, 31.8, 29.6, 27.8, 27.4, 22.8, 20.9, 14.3.  
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NMR SPECTRA 
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